Kurapa kweBioOCUS Medical Group Dual CD19/BCMA CAR-T Kunopa Mhedzisiro Inofadza muRefractory Myasthenia Gravis: Rwendo rweMurwere Mudiki
Myasthenia Gravis (MG) chirwere chisingaperi che autoimmune neuromuscular disorder chinokonzerwa ne autoantibodies (kunyanya anti-acetylcholine receptor antibodies, AchRAb) iyo inokanganisa kutaurirana kwetsinga netsandanyama, zvichikonzera kushanduka-shanduka kwekushaya simba, ptosis, dysphagia, uye muzviitiko zvakakomba kutadza kufema kunotyisidzira hupenyu. Kune varwere vane refractory MG vasina kupindura kune mishonga yemazuva ano yekudzvinyirira immune, IVIG, FcRn inhibitors, kana complement inhibitors, nzira dzekurapa dzakaganhurirwa - kusvika pari zvino.
Kurapa kweBIOOCUS Medical Group's dual-target CD19/BCMA CAR-T kunomiririra nzira itsva yekurapa maseru e autologous iyo inobvisa masero eB ane pathogenic uye masero eplasma ane chekuita nekugadzirwa kweautoantibodies. Iyi nzira ye dual-target inopa mukana wekuregererwa kwakadzama uye kwenguva refu nekubata zvese zvikamu zvemasero uye zvehumoral zve autoimmune response.
Nyaya inoratidza vimbiso yekurapa. Murwere wechikadzi ane makore makumi maviri ekuberekwa, anonzi LYN, akaonekwa aine refractory Myasthenia Gravis (CNGIIIa, AchRAb-positive) uye post-surgical B3-type thymoma/thymic hyperplasia. Aivewo nezvirwere zvinosanganisira osteoporosis, bilateral femoral head uye left proximal tibial avascular necrosis, uye iron-deficiency anemia. Pasinei nekurapwa kwakawanda kubva muna 2019 kusvika 2025—kusanganisira high dose steroids pamwe neazathioprine, tacrolimus, cyclosporine, repeated IVIG, efgartigimod, eculizumab pamwe netelitacicept, uye rituximab (500 mg)—chirwere chake chakaramba chisina kudzoreka.
Muna Mbudzi 2025, chirongwa cheCAR-T chakatangwa uye cyclosporine yakamiswa. Masero eropa emunonuclear akatorwa musi wa1 Zvita, 2025. Musi wa15 Zvita, 2025, akapihwa CD19 CAR-T (0.5×10⁶/kg) pamwe chete neBCMA CAR-T (1×10⁶/kg). Hapana zviitiko zvakaipa zvakaonekwa mushure mekupihwa mushonga uyu.
Pakazosvika Kurume 2026, ongororo dzakatevera dzakaratidza kuwedzera kweCAR-T nekukurumidza mukati memuviri, neCD19 CAR-T yepamusoro pazuva rechi10 (7.62%, 4.622×10⁷/L) uye BCMA CAR-T pazuva rechi10 (17.17%, 1.0414×10⁸/L), zvakaramba zviripo kusvika mwedzi wechitatu. Kuvandudzika murabhoritari kwaisanganisira kudzikira kukuru kwemazinga eAchRAb uye huwandu hweB-lymphocyte, nehuwandu hweropa hwakagadzikana, mashandiro echiropa neitsvo. Mukurapa, kuwedzera kwakakosha kwakanyorwa muQuantitative Myasthenia Gravis (QMG) uye Activities of Daily Living (ADL). Zviratidzo zvakaita se diplopia, kuomarara kwechiso, dysarthria, uye kuneta kwemakumbo zvakaratidza kupera kana kuvandudzika kwakakura.
Nyaya iyi inoratidza kugona kwekurapa kweBIOOCUS Medical Group's dual-target CD19/BCMA CAR-T mukuwana deep immune reset uye kubatsira kwakakosha mukurapa kweMG isingarapike. Kurapa uku kunobvumirwa zvakanaka, pasina CRS kana neurotoxicity yakaonekwa, uye kune vimbiso yekuregererwa kwenguva refu ukuwo kuchideredza kudiwa kwe chronic immunosuppression.